Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Patiromer allows more CKD patients to continue on spironolactone

Publish date:: October 21, 2019

Key clinical point: Patients with chronic kidney disease and resistant hypertension may stay on spironolactone longer with patiromer.

Major finding: After 12 weeks, 86% of the patiromer patients remained on spironolactone, vs. 66% of the placebo patients, for a significant between-group difference of 19.5% (P less than .0001).

Study details: AMBER, a randomized trial.

Disclosures: Funding for AMBER came from Relypsa, which markets patiromer (Veltassa). Dr. Williams reported consulting for Relypsa during the conduct of the study.

Citation:

Williams B. HFSA 2019.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Cardiology

Sac/val heart failure benefit extends to diabetes patients,

Sedentary postmenopausal women have higher heart failure risk,

Experts disagree with USPSTF’s take on pediatric blood pressure screening,

GALACTIC-HF: New ‘myotropic’ drug class shows modest HFrEF benefit,

Don’t miss cardiovascular risk factors in transgender patients,